Expert perspectives on the evolving treatment landscape of HR+ breast cancer and how novel therapies have been incorporated in practice.
EP. 1: Best Practices for Molecular Testing in Early-Stage Breast Cancer
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
EP. 2: How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer
A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.
EP. 3: Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial
Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.
EP. 4: How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer
A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.
EP. 5: HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches
Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.
EP. 6: Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer
Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.
EP. 7: Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
EP. 8: Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer
Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.
EP. 9: HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners
Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.
EP. 10: Other Treatment Modalities for HR+ Metastatic Breast Cancer
Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.
EP. 11: Evolution in the Field of HR+ Breast Cancer Management
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
2 Clarke Drive Cranbury, NJ 08512